Augmenting vaccine efficacy: Tailored immune strategy with alum-stabilized Pickering emulsion
- PMID: 38876839
- DOI: 10.1016/j.vaccine.2024.05.070
Augmenting vaccine efficacy: Tailored immune strategy with alum-stabilized Pickering emulsion
Abstract
Background: The achievement of optimal vaccine efficacy is contingent upon the collaborative interactions between T and B cells in adaptive immunity. Although multiple immunization strategies have been proposed, there is a notable scarcity of comprehensive investigations pertaining to enhance immune effects through immune strategy adjustments for individual vaccine.
Methods: The hierarchically structured aluminum hydroxide microgel-stabilized Pickering emulsion (ASPE) was prepared by ultrasonic method. This study explored the influence of the immune strategy of ASPE to immune responses, including antigen exposure pattern, adjuvants and antigen dosage, and administration interval.
Results: The findings revealed that external antigen adsorption facilitated increased exposure of antigen epitopes, leading to elevated IgG titers and secretion of cytokines such as interferon-gamma (IFN-γ) or interleukin-4 (IL-4). Additionally, even a low dose (1 μg/dose) of antigens of ASPE boosted sufficient neutralizing antibody levels and memory T cells compared to high-dose antigens, which consistent with the adjuvant dosage effect. Furthermore, maintaining a 4-week immunization interval yielded optimal levels of antigen-specific IgG titers in both short-term and long-term scenarios, as compared to intervals of 2, 3, and 5 weeks. A consistent trend was observed in the proliferation of memory B cells, reaching a superior level at the 4-week interval, which could enhance protection against viral re-infection.
Conclusion: Tailoring immunization strategies for specific vaccines has emerged as powerful driver in maximizing vaccine efficacy and eliciting robust immune responses, thereby presenting cutting-edge approaches to enhanced vaccination.
Keywords: Adjuvant; Alum stabilized-Pickering emulsion; Immune strategy; Vaccine.
Copyright © 2024 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Boosting the immune response in COVID-19 vaccines via an Alum:CpG complex adjuvant.Antiviral Res. 2024 Sep;229:105954. doi: 10.1016/j.antiviral.2024.105954. Epub 2024 Jul 2. Antiviral Res. 2024. PMID: 38964615
-
Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.Vaccine. 2012 Jun 13;30(28):4127-34. doi: 10.1016/j.vaccine.2012.04.079. Epub 2012 May 1. Vaccine. 2012. PMID: 22561312
-
Vaccine-Induced Th1-Type Response Protects against Invasive Group A Streptococcus Infection in the Absence of Opsonizing Antibodies.mBio. 2020 Mar 10;11(2):e00122-20. doi: 10.1128/mBio.00122-20. mBio. 2020. PMID: 32156809 Free PMC article.
-
Dual-antigen fusion protein vaccination induces protective immunity against Candida albicans infection in mice.Hum Vaccin Immunother. 2024 Dec 31;20(1):2406065. doi: 10.1080/21645515.2024.2406065. Epub 2024 Sep 26. Hum Vaccin Immunother. 2024. PMID: 39327639 Free PMC article.
-
Re-inventing traditional aluminum-based adjuvants: Insight into a century of advancements.Int Rev Immunol. 2025;44(2):58-81. doi: 10.1080/08830185.2024.2404095. Epub 2024 Sep 23. Int Rev Immunol. 2025. PMID: 39310923 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources